2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2471

Sustained Response in a Phase 3 Study of Sarilumab Plus Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Abstract Number: 2879

Switching from Adalimumab to Chs-1420: A Randomized, Double-Blind Global Clinical Trial in Patients with Psoriasis and Psoriatic Arthritis
Abstract Number: 2439

Switching from RA Originator to Biosimilar in Routine Clinical Care: Early Data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Abstract Number: 1430

Switching from Synthetic to Biologic Dmards – Is There an Insufficient Use of Methotrexate?
Abstract Number: 1348

Swollen Joint Count, but Not Inflammatory Cytokines, Differs By Frequency of Fish Consumption in a Cross-Sectional Rheumatoid Arthritis Cohort
Abstract Number: 1178

Sympathetic Joint Effusion in an Urban Hospital
Abstract Number: 728

Symptoms of Autonomic Dysfunction in Systemic Sclerosis Assessed By the Compass-31 Questionnaire
Abstract Number: 2315

Symptoms of Depression and Anxiety in Children with JIA: Relation to Other Domains of Health Related Quality of Life
Abstract Number: 2894

Synchronous Telemedicine Care in Rheumatology for a Dispersed Veterans Affairs Health System
Abstract Number: 890

Synergetic B-Cell Immunomodulation with Rituximab and Belimumab Combination Treatment in Severe, Refractory SLE
Abstract Number: 1456

Synergistic Reversal of Arthritis By Synoviocyte-Targeted Therapy and TNF Immunomodulation
Abstract Number: 971

Synovial Fibroblast CD318 Expression Mediates T Cell Adhesion and Migration in Rheumatoid Arthritis
Abstract Number: 2081

Synovial Fluid Leukocyte Count and Its Association with Crystal Deposition in Asymptomatic Hyperuricemia
Abstract Number: 1101

Systematic Physician Assessment Beyond Inflammation in Routine Rheumatology Care Using Visual Analog Scale Scores for Inflammation, Damage, and Distress to Document Patient Status and Support Clinical Decisions: Analysis of Inter-Rater Reliability
Abstract Number: 1052

Systematic Review of Modelling Approaches and Quality for the Cost Effectiveness of sequential Targeted Therapy in Patients with Rheumatoid Arthritis That Show an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].